XML 37 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Balance Sheet Information
12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Balance Sheet Information

5. Supplemental Balance Sheet Information

Property and Equipment

Property and equipment consists of the following (dollar amounts in thousands)

 

 

 

Estimated Useful

 

December 31,

 

 

December 31,

 

 

 

Life (Years)

 

2022

 

 

2021

 

Office and computer equipment

 

3

 

$

757

 

 

$

749

 

Software

 

3

 

 

783

 

 

 

783

 

Laboratory equipment

 

5

 

 

5,570

 

 

 

5,507

 

Furniture

 

5-7

 

 

197

 

 

 

197

 

Manufacturing equipment

 

5

 

 

1,454

 

 

 

1,445

 

Manufacturing tooling and molds

 

0.5-5

 

 

494

 

 

 

478

 

T2-owned instruments and components

 

5

 

 

4,052

 

 

 

5,327

 

Leased T2-owned instruments

 

5

 

 

1,014

 

 

 

886

 

Leasehold improvements

 

Lesser of useful life or remaining lease term

 

 

3,784

 

 

 

3,768

 

Construction in progress

 

n/a

 

 

685

 

 

 

512

 

 

 

 

 

 

18,790

 

 

 

19,652

 

Less accumulated depreciation and amortization

 

 

 

 

(14,257

)

 

 

(14,977

)

Property and equipment, net

 

 

 

 

4,533

 

 

$

4,675

 

 

Construction in progress includes $0.8 million and $1.4 million of T2-owned instrument raw materials and work-in-process at December 31, 2022 and 2021, respectively. Depreciation expense, a component of cost of product revenue, from instruments under the T2-owned reagent rental pool was $0.1 million and $0.2 million for the year ended December 31, 2022 and 2021, respectively. Depreciation expense for T2-owned instruments used for internal research and development and clinical studies is recorded as a component of research and development expense. Depreciation and amortization expense of $1.0 million and $1.3 million was charged to operations for the years ended December 31, 2022 and 2021, respectively.

Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Accrued payroll and compensation

 

$

2,930

 

 

$

3,687

 

Accrued clinical trial and development expenses

 

 

1,097

 

 

 

1,250

 

Accrued professional services

 

 

1,626

 

 

 

384

 

Accrued interest

 

 

1,009

 

 

 

974

 

Other accrued expenses

 

 

607

 

 

 

869

 

Total accrued expenses and other current liabilities

 

$

7,269

 

 

$

7,164

 

 

Accrued professional services includes a $1.0 million estimated liability related to the Billerica, Massachusetts lease (Note 12).